EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices

Amie R Throneberry, Bradley G Burk, Brandon S Pruett

Frontiers in Psychiatry · 01.09.2025 · 16

DOI: 10.3389/fpsyt.2025.1659290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 01.09.2025. Verfasst von Amie R Throneberry und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Translational Science, University of Tennessee Health Science Center College of Pharmacy, Nashville, TN, United Sta…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting injectable antipsychotics (LAI-APs) are vital for managing psychiatric conditions, particularly in patients with adherence challenges. However, errors in medication reconciliation, prescribing, preparation, and administration, often stemming from documentation lapses and communication breakdowns, may result in an increased risk of relapse or readmission. Despite their widespread use, standardized documentation practices remain underdeveloped.

Objective

To identify documentation insufficiencies related to LAI-AP use across healthcare settings and propose best practice recommendations to improve safety and care continuity.

Methods

A comprehensive review of literature using PubMed, Google Scholar, current clinical guidelines, and gray literature was conducted to identify safety concerns and documentation gaps related to LAI-APs. Search terms included “LAI antipsychotic medication errors,” “documentation,” “safety,” “mental health,” and “medication reconciliation.” Further articles were identified through a scan of the references cited within the initial sources. From this analysis, a series of best practice recommendations were developed targeting key aspects of LAI-AP use, with a focus on practical implementation strategies.

Results

Limited literature is available on errors related to LAI-AP with minimal detail on documentation strategies to address these. By reviewing reports, extrapolating recommendations from their oral antipsychotic counterparts, and analyzing potential risk factors unique to the behavioral health setting, key documentation gaps were identified across the LAI-AP use process. These include deficiencies in medication reconciliation—especially related to last doses and oral overlap—along with inconsistencies in prescribing practices, patient education, preparation, administration, and transitions of care. Inadequate documentation contributes to missed or duplicate doses, incorrect administration techniques, and poor coordination between settings. Our findings indicate the need for standardized order sets, readily accessible documentation of initiation or discontinuation reasoning, integration of therapeutic drug monitoring and symptom tracking tools, structured patient education, and formalized transitions of care procedures.

Conclusions

Enhancing documentation throughout the LAI-AP care continuum is crucial to reduce medication errors and improve patient outcomes. The proposed framework offers practical steps for clinicians and health systems to standardize documentation, improve communication during care transitions, and promote safer LAI-AP use. Innovations such as national electronic health records, EHR-integrated LAI-AP registries, and smartphone apps could facilitate cross-setting communication, patient engagement, and error reduction. Addressing systemic barriers will require policy-level reform.

Schlagwörter

Stichwörter der Autor:innen

EHR interoperabilityantipsychotic depotsbest practicesdocumentationlong-acting injectable antipsychoticsmedication reconciliationpsychiatric medication safetytransitions of care

Autor:innen und Institutionen

  • Department of Clinical Pharmacy & Translational Science, University of Tennessee Health Science Center College of Pharmacy, Nashville, TN, United States.
  • Department of Pharmacy, University of Alabama at Birmingham Medical Center, Birmingham, AL, United States.
  • Department of Psychiatry and Behavioral Neurobiology, University of Alabama Max Heersink School of Medicine, Birmingham, AL, United States.

Zitieren

APA

Throneberry, A. R., Burk, B. G., & Pruett, B. S. (2025). Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1659290

Vancouver

Throneberry AR, Burk BG, Pruett BS. Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices. Frontiers in Psychiatry. 2025;16. doi:10.3389/fpsyt.2025.1659290

BibTeX
@article{Throneberry2025,
  author = {Throneberry, Amie R and Burk, Bradley G and Pruett, Brandon S},
  title = {Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices},
  journal = {Frontiers in Psychiatry},
  year = {2025},
  volume = {16},
  doi = {10.3389/fpsyt.2025.1659290}
}
Kostenlos starten →